Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AbbVie Inc. | Venclexta (venetoclax) | Multiple myeloma | Phase 3 | Data Released | Oral | Oncology |
| AbbVie Inc. | EPKINLY (epcoritamab-bysp) - (DLBCL-1 ) | Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) | Phase 3 | Data Released | Subcutaneous | Oncology |
| AbbVie Inc. | RINVOQ (upadacitinib) versus HUMIRA (adalimumab) - (SELECT-SWITCH) | Rheumatoid arthritis (RA) | Phase 3 | Data Released | RINVOQ oral HUMIRA subcutaneous | Immunology: Anti-TNF |
| AbbVie Inc. | Atogepant (QULIPTA/AQUIPTA) | Migraine Prevention | Phase 3 | Data Released | Oral | Neurology |
| AbbVie Inc. | ABBV-383 - (CERVINO) | Multiple myeloma | Phase 3 | Ongoing | Intravenous | Oncology |
| AbbVie Inc. | SKYRIZI (risankizumab) - (SEQUENCE) | Crohn's disease | Phase 3 | Data Released | Subcutaneous | Gastroenterology |
| AbbVie Inc. | Atogepant - (ELEVATE) | Episodic Migraine | Phase 3 | Data Released | Oral | Neurology |
| AbbVie Inc. | RINVOQ (upadacitinib) | Moderate-to-Severe Hidradenitis Suppurativa | Phase 3 | Enrollment Initiation | Oral | Immunology |
